X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $143.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 24, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 19, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 18, 2023
Details:
Updated Results for DCC-3014 (vimseltinib) Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Details:
DCC-3014 (vimseltinib) is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the CSF1R switch pocket.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Deciphera intends to use the net proceeds from the offering to continue to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway, additional clinical trials.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 29, 2022
Details:
Deciphera intends to use the net proceeds from the offering to continue to fund the development of DCC-3014 (vimseltinib) in its pivotal Phase 3 MOTION study in tenosynovial giant cell tumor patients and medical affairs capabilities related to vimseltinib.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 27, 2022
Details:
A CSF1R kinase inhibitor for tenosynovial giant cell tumor (TGCT) Vimseltinib is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2021
Details:
The Company’s international, multicenter, open-label Phase 1/2 study of DCC-3014 was designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of DCC-3014 in patients with malignant solid tumors and TGCT.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
